DEUTSCHE-POST-DHL-GROUP
Deutsche Post DHL Group (Symbol: DPW), the world’s leading logistics company, has today released preliminary results for the third quarter of 2021. The Group’s EBIT reached around EUR 1.765 billion in the third quarter 2021 (Q3 2020: EUR 1.377 billion), bringing the EBIT of the first nine months of 2021 to around EUR 5.760 billion. This includes a one-off effect of EUR -179 million for the second Covid-19 bonus (Q3 2020: EUR -163 million), which will be paid in the fourth quarter. Against the backdrop of the excellent business development, the Group will revise upward its outlook for EBIT and free cash flow for FY 2021. In addition, the mid-term guidance for FY 2023 will be increased on November 4, 2021.
“In the first nine months of the current year, we have already exceeded previous year’s full-year result. Global trade accelerated significantly compared to the previous year. At the same time, shipment volumes in e-commerce remained high. Therefore we are optimistic for the oncoming peak season“, said Frank Appel, CEO of Deutsche Post DHL Group. “We are now intensively preparing ourselves for potential record breaking shipment volumes in the coming weeks and have deliberately built up capacity in the third quarter, in order to be able to offer our customers continued high quality service.”
DHL divisions achieved a significant jump in earnings
The positive development of the group's businesses seen in the first half of the year has continued well through the third quarter 2021. All DHL divisions significantly exceeded the previous year's results. Volume trends in the past quarter confirm base assumptions with continued well supported B2B recovery and B2C volumes staying at high previous year levels across all major networks. At the same time the tight capacity situation both in Ocean and Air Freight markets continued.
Express: EBIT in the Express division reached around EUR 970 million in the third quarter 2021 compared to EUR 753 million in the previous year’s quarter.
Global Forwarding, Freight: EBIT in Global Forwarding, Freight stood at around EUR 370 million in the third quarter 2021, also clearly ahead of previous year’s result of EUR 155 million.
Supply Chain: EBIT at Supply Chain came in at around EUR 140 million in the third quarter 2021, significantly above last year's third quarter result which stood at EUR 112 million.
eCommerce Solutions: eCommerce Solutions recorded EBIT of around EUR 90 million in the third quarter 2021, significantly above last year’s third quarter result which stood at EUR 76 million.
Post & Parcel Germany: EBIT in Post & Parcel Germany in the third quarter 2021 was around EUR 300 million (Q3 2020: EUR 320 million).
The continued positive business development is underpinned by a continued equally strong development of cash flow; free cash flow in the third quarter 2021 amounted to more than EUR 1.0 billion (Q3 2020: EUR 1.264 billion). For the first nine months of 2021 free cash flow stands at more than EUR 3.1 billion and significantly exceeds the previous year result (9M 2020: EUR 1.460 billion).
Earnings and FCF outlook will be revised upwards based on dynamic business performance
In light of the continued positive earnings momentum also in the third quarter 2021, management will raise guidance for FY 2021 Group EBIT and FCF, driven by the strong development in the DHL divisions. Also, the mid-term guidance for FY 2023 will be subject to upward revision.
The comprehensive disclosure for third quarter 2021 will be published as planned on November 4, 2021.
– End –
Deutsche Post DHL Group is the world’s leading logistics company. The Group connects people and markets and is an enabler of global trade. It aspires to be the first choice for customers, employees and investors worldwide. The Group contributes to the world through responsible business practice, corporate citizenship and environmental activities. By the year 2050, Deutsche Post DHL Group aims to achieve zero emissions logistics.
Deutsche Post DHL Group is home to two strong brands: Deutsche Post is Europe’s leading postal service. DHL offers a comprehensive range of international express, freight transport, and supply chain management services as well as e-commerce logistics solutions. Deutsche Post DHL Group employs approximately 570,000 people in over 220 countries and territories worldwide. The Group generated revenues of more than 66 billion Euros in 2020.
THE logistics company for the world.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211007005668/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NHOA Energy Achieves Great Place To Work Certification in Italy, the United States and Australia18.12.2025 10:53:00 CET | Press release
NHOA Energy, global provider of utility-scale energy storage systems, announces that it has been certified Great Place To Work® in Italy, the United States, and Australia. The certification is based entirely on direct feedback from NHOA Energy employees, gathered through an independent and structured listening process. Great Place To Work® Certification™ assesses the quality of the employee experience across key dimensions such as credibility, respect, fairness, pride, and camaraderie. The results achieved by NHOA Energy reflect a corporate culture built on trust, inclusion, and the consistent commitment to valuing people within a dynamic and international environment. Employees highlighted particularly high levels of appreciation for the ethical and transparent behavior of leaders, the welcoming and inclusive approach toward new hires, and fair treatment across diversity, equity, and inclusion dimensions. A strong majority also expressed pride in working at NHOA Energy and reported a
Regnology Signs an Agreement to Acquire Moody’s Regulatory Reporting & ALM Solutions18.12.2025 10:00:00 CET | Press release
The deal further strengthens Regnology’s global position in Regulatory Reporting and significantly accelerates its expansion into new markets Regnology, a leading provider in regulatory, risk, tax, and finance reporting, as well as supervisory technology, today announced it has signed an exclusive agreement for the acquisition of Moody’s Regulatory Reporting & ALM Solutions business, inclusive of solutions for Basel III compliance, IFRS9 impairment accounting, large bank asset-liability management (ALM), Solvency II insurance reporting, and prudential and statistical regulatory reporting across more than 50 jurisdictions. By integrating Moody’s regulatory capital and liquidity capabilities with Regnology’s regulatory, risk, and finance offerings, the firm is creating a unified, scalable platform designed to meet the full spectrum of financial regulatory compliance and risk requirements. This combined strength positions Regnology as the partner of choice for financial institutions seeki
Reply Recognized as a Microsoft Azure Expert Managed Services Provider for the Sixth Consecutive Year18.12.2025 10:00:00 CET | Press release
Reply [EXM, STAR: REY] announced today it has been recognized once again as a Microsoft Azure Expert Managed Services Provider (MSP). The renewal reaffirms Reply’s proven expertise and consistent track record in delivering high-quality cloud solutions and services on the Microsoft Azure platform, powered by the deep technical expertise of its specialized companies – Cluster Reply, Solidsoft Reply and Valorem Reply. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218596617/en/ This recognition reflects the ongoing collaboration between Reply - through its companies Cluster Reply, Solidsoft Reply, and Valorem Reply - and Microsoft, supporting shared efforts to deliver value-driven services to enterprise customers. The Azure Expert MSP program is designed by Microsoft to identify and validate partners with proven capabilities in delivering end-to-end Azure services at scale. To qualify, partners must meet a strict set of requ
Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 09:00:00 CET | Press release
Pivotal Phase 3 studies of once-daily oral zasocitinib met all primary and ranked secondary endpoints in patients with moderate-to-severe plaque psoriasis More than half of study participants treated with zasocitinib achieved clear or almost clear skin (PASI 90), and on average about 30 percent achieved completely clear skin (PASI 100) by week 16 Zasocitinib was generally well-tolerated with a safety profile consistent with previous clinical studies Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at wee
DATROWAY® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy18.12.2025 08:30:00 CET | Press release
Based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s DATROWAY is the first and only medicine to significantly improve overall survival versus chemotherapy in this patient population If approved, DATROWAY could become the standard of care in this setting The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for DATROWAY® (datopotamab deruxtecan) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. DATROWAY is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committee for Medicinal Produc
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom